Iovance to Present at Investor Conferences in September

SAN CARLOS, Calif., Sept. 04, 2026 /CourierPR/ -- Iovance Biotherapeutics, Inc., the global leader in tumor infiltrating lymphocyte (TIL) cell therapies, will present at two upcoming investor conferences in September 2026, offering insights into its innovative cancer treatments.

Amtagvi® (lifileucel), the first FDA-approved, one-time treatment for previously treated advanced melanoma, has now been approved in three global markets and is available at more than 95 authorized treatment centers. The company’s Iovance TIL platform includes registrational trials and next-generation programs in additional solid tumors, such as gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches.

Iovance operates as an end-to-end cell therapy company, with a fully owned, centralized U.S.-based manufacturing facility that can serve thousands of cancer patients annually. The company’s intellectual property portfolio is broad and industry-leading, and detailed information can be found on its website.

Forward-looking statements made in this press release are based on current expectations and may include uncertainties and risks that could affect actual outcomes. Iovance Biotherapeutics cautions readers that such statements are not guarantees and actual results may differ significantly.